<DOC>
	<DOCNO>NCT00410631</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy work different way stop growth tumor cell , either kill cell stop divide . Giving combination chemotherapy may kill tumor cell . Radiation therapy use high-energy x-ray kill tumor cell . An autologous stem cell transplant may able replace blood-forming cell destroy chemotherapy radiation therapy . This may allow chemotherapy give tumor cell kill . Sometimes , surgery , tumor may need treatment progress . In case , observation may sufficient . It yet know whether observation effective combination chemotherapy , radiation therapy , and/or autologous stem cell transplant treat neuroblastoma . PURPOSE : This randomized phase III phase IV trial study observation , combination chemotherapy , radiation therapy , and/or autologous stem cell transplant compare well work treat young patient neuroblastoma .</brief_summary>
	<brief_title>Observation , Combination Chemotherapy , Radiation Therapy , and/or Autologous Stem Cell Transplant Treating Young Patients With Neuroblastoma</brief_title>
	<detailed_description>OBJECTIVES : Primary - Determine event-free survival ( EFS ) young patient newly diagnose neuroblastoma categorized low-risk group ( LRG ) undergo observation receive combination chemotherapy . - Compare EFS rate patient neuroblastoma categorized medium-risk group ( MRG ) treat combination induction therapy , maintenance therapy , consolidation therapy historical control group . - Compare EFS patient neuroblastoma categorized high-risk group ( HRG ) treat standard v experimental induction therapy follow autologous stem cell transplantation consolidation therapy . Secondary - Determine locoregional EFS patient LRG , MRG , HRG . - Determine overall survival patient . - Determine extent initial surgery , extent impact best surgery , surgery-related complication patient . - Determine time transition stage 4 disease patient LRG MRG . - Determine time locoregional event patient LRG HRG . - Determine time diagnosis event patient LRG . - Determine time begin regression adverse event patient LRG . - Determine time begin primary tumor regression patient LRG . - Determine time normalization tumor marker patient LRG . - Determine time evidence disease patient LRG stage 4S disease . - Assess status primary tumor 12 month best status primary tumor within 12 month patient LRG . - Determine need chemotherapy control progression intensity therapy require patient LRG . - Determine acute late side effect external-beam radiotherapy patient MRG HRG . - Determine response induction therapy patient HRG . - Assess early response 2 course induction therapy patient HRG . - Determine toxicity induction course 1 2 frequency grade 3 4 toxicity induction therapy patient HRG . - Assess efficacy iodine I 131 metaiodobenzylguanidine ( MIBG ) therapy , term activity whole body dose , patient HRG . - Assess molecular marker ( e.g. , chromosome 1p , chromosome 11q , neuroblastoma gene chip ) patient . OUTLINE : This prospective , historically control , randomize , open-label , multicenter study . Patients stratify accord disease risk ( low-risk v medium-risk vs high-risk ) . - Low-risk group : Patients undergo complete stag 3 month initial surgery . Patients progression observe 12 month ( patient 1 year age ) end second year life ( patient 1 year age young ) . Patients localized progression threaten symptom undergo N4 chemotherapy comprise doxorubicin hydrochloride IV 30 minute vincristine IV day 1 , 3 , 5 cyclophosphamide IV 30 minute day 1-7 . Treatment repeat every 21 day 4 course . Patients reassess course N4 chemotherapy . Patients achieve stable disease tumor regression point discontinue N4 chemotherapy undergo observation . Patients persistent progressive disease 4 course N4 chemotherapy proceed treatment medium-risk group . Patients progress stage 4 disease initial surgery proceed treatment medium-risk group ( patient 1 year age young indication stage 4S disease ) high-risk group ( patient 1 year age ) . - Medium-risk group : Patients receive induction therapy follow maintenance therapy consolidation therapy . - Induction therapy : Patients* receive N5 chemotherapy comprise cisplatin IV continuously 96 hour etoposide phosphate IV continuously 96 hour day 1-4 , vindesine IV 1 hour day 1 , filgrastim ( G-CSF ) subcutaneously ( SC ) begin day 9 continue blood count recover . Patients receive N6 chemotherapy comprise vincristine IV 1 hour day 1 8 , dacarbazine IV 1 hour ifosfamide IV continuously 120 hour day 1-5 , doxorubicin hydrochloride IV 4 hour day 6 7 , G-CSF begin day 10 continue blood count recover . Treatment repeat every 21 day alternate N5 N6 chemotherapy 6 total course ( 3 course N5 N6 ) . Patients proceed maintenance therapy . NOTE : *Patients 6 month age receive 4 course N4 chemotherapy ( low-risk group ) instead N5/N6 chemotherapy reach 6 month age . Patients active residual tumor induction chemotherapy undergo external-beam radiotherapy ( EBRT ) 25 fraction concurrently maintenance chemotherapy . Secondary surgery resection primary tumor attempt course 4 6 induction therapy EBRT . - Maintenance therapy : Patients receive N7 chemotherapy comprise cyclophosphamide orally IV 1 hour day 1-8 . Treatment repeat every 21 day 4 course absence disease progression unacceptable toxicity . - Consolidation therapy : Beginning 21 day completion maintenance therapy , patient receive oral isotretinoin 2-3 time daily day 1-14 . Treatment repeat every 28 day 6 course absence unacceptable toxicity . Patients receive 3 additional course 3-months rest . - High-risk group : Patients receive induction therapy follow autologous stem cell transplantation ( ASCT ) consolidation therapy . - Induction therapy : Patients 1 year age randomize 1 2 treatment arm . Patients 1 year age undergo randomization ; instead assign arm I . - Arm I ( standard ) : Patients* receive N5 N6 chemotherapy induction therapy medium-risk group . - Arm II ( experimental ) : Patients receive N8 chemotherapy comprise topotecan hydrochloride IV continuously 168 hour cyclophosphamide IV 1 hour day 1-7 , etoposide IV 1 hour day 8-10 , G-CSF SC begin day 12 continue blood count recover . Treatment repeat every 21 day 2 course . Patients receive N5 N6 chemotherapy induction therapy medium-risk group . In arm , patient active residual primary tumor 6 course induction therapy undergo iodine I 131 metaiodobenzylguanidine ( MIBG ) ** radiotherapy ( ASCT ) . Patients also undergo EBRT 25 fraction ASCT . Secondary surgery resection primary tumor attempt course 4 6 induction therapy radiotherapy . NOTE : *Patients 6 month age receive 4 course N4 chemotherapy ( low-risk group ) instead N5/N6 chemotherapy reach 6 month age . NOTE : **Patients MIBG-negative disease undergo EBRT . - Conditioning follow ASCT : Patients receive melphalan IV 30 minute day -8 -5 , etoposide phosphate IV 4 hour day -4 , carboplatin IV 1 hour day -4 -2 . Patients undergo ASCT day 0 . Patients receive G-CSF SC begin day 2 continue blood count recover . - Consolidation therapy : Beginning 30 day ASCT , patient receive isotretinoin* consolidation therapy medium-risk group . NOTE : *Isotretinoin discontinue EBRT restart 1 week completion EBRT . After completion study treatment , patient follow periodically . PROJECTED ACCRUAL : A total 642 patient accrue study .</detailed_description>
	<mesh_term>Neuroblastoma</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Melphalan</mesh_term>
	<mesh_term>Ifosfamide</mesh_term>
	<mesh_term>Liposomal doxorubicin</mesh_term>
	<mesh_term>Etoposide phosphate</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<mesh_term>Doxorubicin</mesh_term>
	<mesh_term>Etoposide</mesh_term>
	<mesh_term>3-Iodobenzylguanidine</mesh_term>
	<mesh_term>Vincristine</mesh_term>
	<mesh_term>Topotecan</mesh_term>
	<mesh_term>Vindesine</mesh_term>
	<mesh_term>Isotretinoin</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Diagnosis neuroblastoma histology use tumor tissue evidence presence distinct neuroblastoma cell bone marrow AND elevate catecholamine metabolite ( i.e. , homovanillic acid [ HVA ] vanillylmandelic acid [ VMA ] ) blood urine Newly diagnose disease ( patient lowrisk group ) Diagnosis tumor tissue ( patient mediumrisk group ) Meets criteria 1 follow risk group : Lowrisk group No MYCN amplification AND meet 1 follow criterion : Stage 1 disease Stage 2 disease chromosome 1p deletion imbalance Stage 3 disease chromosome 1p deletion imbalance ( patient &lt; 2 year age ) Stage 4S disease ( patient &lt; 1 year age ) Mediumrisk group No MYCN amplification AND meet 1 follow criterion : Stage 2 disease chromosome 1p deletion imbalance Stage 3 disease chromosome 1p deletion imbalance Any chromosome 1p status ( patient ≥ 2 year age ) Stage 4 disease ( patient &lt; 1 year age ) Highrisk group , meet 1 follow criterion : Any stage disease MYCN amplification Any MYCN status ( patient ≥ 1 year age ) PATIENT CHARACTERISTICS : Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception PRIOR CONCURRENT THERAPY : No prior nephrectomy mutilate surgery initial surgery ( patient lowrisk group ) No concurrent anticancer therapy</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>21 Years</maximum_age>
	<verification_date>January 2008</verification_date>
	<keyword>localize resectable neuroblastoma</keyword>
	<keyword>localize unresectable neuroblastoma</keyword>
	<keyword>regional neuroblastoma</keyword>
	<keyword>stage 4S neuroblastoma</keyword>
	<keyword>disseminate neuroblastoma</keyword>
	<keyword>recurrent neuroblastoma</keyword>
</DOC>